Presentation is loading. Please wait.

Presentation is loading. Please wait.

Activation of Endothelial and Coagulation Systems in Left Ventricular Assist Device Recipients  Ranjit John, MD, Sandhya Panch, MBBS, Jennifer Hrabe,

Published byΚυριακή Βιλαέτης Modified over 5 years ago

Similar presentations

Presentation on theme: "Activation of Endothelial and Coagulation Systems in Left Ventricular Assist Device Recipients  Ranjit John, MD, Sandhya Panch, MBBS, Jennifer Hrabe,"— Presentation transcript:

1 Activation of Endothelial and Coagulation Systems in Left Ventricular Assist Device Recipients 
Ranjit John, MD, Sandhya Panch, MBBS, Jennifer Hrabe, BS, Peng Wei, MPH, Anna Solovey, PhD, Lyle Joyce, MD, PhD, Robert Hebbel, MD  The Annals of Thoracic Surgery  Volume 88, Issue 4, Pages (October 2009) DOI: /j.athoracsur Copyright © 2009 The Society of Thoracic Surgeons Terms and Conditions

2 Fig 1 Circulating endothelial cells (CECs) in blood enumerated by immunohistochemical staining of buffy-coat smears. Surface phenotype was evaluated by immunofluorescence microscopy of circulating endothelial cell preparations. (DAPI = 4',6-diamidino-2-phenylindole.) The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2009 The Society of Thoracic Surgeons Terms and Conditions

3 Fig 2 Measured study markers in relation to the coagulation cascade. (ICAM = intercellular adhesion molecule; PF 1+2 = prothrombin fragments 1,2; TAT = thrombin/antithrombin III; VCAM = vascular cell adhesion molecule; vWA = von Willebrand antigen.) The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2009 The Society of Thoracic Surgeons Terms and Conditions

4 Fig 3 Baseline hematologic data between the two types of left ventricular assist devices. (HM II = HeartMate II; INR = international normalized ratio.) The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2009 The Society of Thoracic Surgeons Terms and Conditions

5 Fig 4 Levels of circulating endothelial cells in 21 left ventricular assist device recipients (day 0 and postoperative days 1, 7, 30, 90, and 180) and in 7 control patients undergoing non–left ventricular assist device cardiac surgery (day 0 and postoperative days 1, 7, and 30). The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2009 The Society of Thoracic Surgeons Terms and Conditions

6 Fig 5 Markers of endothelial activation (intercellular adhesion molecule [ICAM], vascular cell adhesion molecule [VCAM], E-selectin, tissue factor) in 21 left ventricular assist device recipients (day 0 and postoperative days 1, 7, 30, 90, and 180) and in 7 control patients undergoing non–left ventricular assist device cardiac surgery (day 0 and postoperative days 1, 7, and 30). The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2009 The Society of Thoracic Surgeons Terms and Conditions

7 Fig 6 Serum markers (von Willebrand antigen, prothrombin fragments 1,2, D-dimers, and thrombin/antithrombin III) in 21 left ventricular assist device recipients (day 0 and postoperative days 1, 7, 30, 90, and 180) and in 7 control patients undergoing non–left ventricular assist device cardiac surgery (day 0 and postoperative days 1, 7, and 30). The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2009 The Society of Thoracic Surgeons Terms and Conditions

Download ppt "Activation of Endothelial and Coagulation Systems in Left Ventricular Assist Device Recipients  Ranjit John, MD, Sandhya Panch, MBBS, Jennifer Hrabe,"

Similar presentations

Heart Transplant vs Left Ventricular Assist Device in Heart Transplant-Eligible Patients Matthew L. Williams, MD, Jaimin R. Trivedi, MD, MPH, Kelly C.

Heart Transplant vs Left Ventricular Assist Device in Heart Transplant-Eligible Patients Matthew L. Williams, MD, Jaimin R. Trivedi, MD, MPH, Kelly C.
Pulmonary Lobectomy in a Patient With a Left Ventricular Assist Device

Pulmonary Lobectomy in a Patient With a Left Ventricular Assist Device
Survival on the Heart Transplant Waiting List: Impact of Continuous Flow Left Ventricular Assist Device as Bridge to Transplant  Jaimin R. Trivedi, MD,

Survival on the Heart Transplant Waiting List: Impact of Continuous Flow Left Ventricular Assist Device as Bridge to Transplant  Jaimin R. Trivedi, MD,
Fibrinogen Levels After Cardiac Surgical Procedures: Association With Postoperative Bleeding, Trigger Values, and Target Values  Marco Ranucci, MD, Valeria.

Fibrinogen Levels After Cardiac Surgical Procedures: Association With Postoperative Bleeding, Trigger Values, and Target Values  Marco Ranucci, MD, Valeria.
Left Ventricular Assist Device Design Reduces von Willebrand Factor Degradation: A Comparative Study Between the HeartMate II and the EVAHEART Left Ventricular.

Left Ventricular Assist Device Design Reduces von Willebrand Factor Degradation: A Comparative Study Between the HeartMate II and the EVAHEART Left Ventricular.
Pump Replacement for Left Ventricular Assist Device Failure Can Be Done Safely and Is Associated With Low Mortality  Nader Moazami, MD, Carmelo A. Milano,

Pump Replacement for Left Ventricular Assist Device Failure Can Be Done Safely and Is Associated With Low Mortality  Nader Moazami, MD, Carmelo A. Milano,
Laura Harvey, MD, Christopher Holley, MD, Samit S

Laura Harvey, MD, Christopher Holley, MD, Samit S
Jan D. Schmitto, MD, PhD, Jasmin S

Jan D. Schmitto, MD, PhD, Jasmin S
Incidence and Patterns of Adverse Event Onset During the First 60 Days After Ventricular Assist Device Implantation  Elizabeth A. Genovese, BS, Mary Amanda.

Incidence and Patterns of Adverse Event Onset During the First 60 Days After Ventricular Assist Device Implantation  Elizabeth A. Genovese, BS, Mary Amanda.
Continuous Flow Left Ventricular Assist Device Outcomes in Commercial Use Compared With the Prior Clinical Trial  Ranjit John, MD, Yoshifumi Naka, MD,

Continuous Flow Left Ventricular Assist Device Outcomes in Commercial Use Compared With the Prior Clinical Trial  Ranjit John, MD, Yoshifumi Naka, MD,
Benjamin E. Lee, MD, Mark Shapiro, MD, John R. Rutledge, MAS, Robert J

Benjamin E. Lee, MD, Mark Shapiro, MD, John R. Rutledge, MAS, Robert J
Age of Transfused Red Cells and Early Outcomes After Cardiac Surgery

Age of Transfused Red Cells and Early Outcomes After Cardiac Surgery
Invited Commentary The Annals of Thoracic Surgery

Invited Commentary The Annals of Thoracic Surgery
Acquired von Willebrand Syndrome in Continuous-Flow Ventricular Assist Device Recipients  Sheri Crow, MD, Dong Chen, MD, PhD, Carmelo Milano, MD, William.

Acquired von Willebrand Syndrome in Continuous-Flow Ventricular Assist Device Recipients  Sheri Crow, MD, Dong Chen, MD, PhD, Carmelo Milano, MD, William.
Improved Approach With Subcostal Exchange of the HeartMate II Left Ventricular Assist Device: Difference in On and Off Pump?  Ann C. Gaffey, MD, MTR,

Improved Approach With Subcostal Exchange of the HeartMate II Left Ventricular Assist Device: Difference in On and Off Pump?  Ann C. Gaffey, MD, MTR,
Sharven Taghavi, MD, MPH, Charisse Ward, MD, Senthil N

Sharven Taghavi, MD, MPH, Charisse Ward, MD, Senthil N
Michael L. Bailey, MBBS, Sven M. Richter, MD, Daniel V

Michael L. Bailey, MBBS, Sven M. Richter, MD, Daniel V
John S. Ikonomidis, MD, PhD, Niv Ad, MD, Gabriel S

John S. Ikonomidis, MD, PhD, Niv Ad, MD, Gabriel S
Surgical Ventricular Restoration for Advanced Congestive Heart Failure: Should Pulmonary Hypertension Be a Contraindication?  Nishant D. Patel, BA, Jason.

Surgical Ventricular Restoration for Advanced Congestive Heart Failure: Should Pulmonary Hypertension Be a Contraindication?  Nishant D. Patel, BA, Jason.
Javed Butler, MD, Carrie Geisberg, MD, Renee Howser, MSN, Peer M

Javed Butler, MD, Carrie Geisberg, MD, Renee Howser, MSN, Peer M

Similar presentations

Ads by Google